PHR — Pharmena SA Share Price
Last trade - 00:00- PLN33.30m
- PLN27.69m
- PLN1.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.08 | ||
| Price to Tang. Book | 5.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 22.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.45% | ||
| Return on Equity | -31.51% | ||
| Operating Margin | -228.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 15.21 | 0.3 | 1.25 | 0.27 | 1.58 | n/a | n/a | -30.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharmena SA is a Poland-based pharmaceutical and life science company specializing in the research, development, and commercialization of products and technologies derived from scientific research, particularly in the areas of healthy aging, bioscience, and topical technologies. The Company is structured around research and development activities focused on the biological and therapeutic potential of 1-methylnicotinamide (1-MNA), a naturally occurring metabolite of niacin, and develops dietary supplements, health-related products, and drug candidates based on this technology. The Company's core activity centers on the application of 1-MNA technology, including products marketed under the Endotelio and Menavitin product lines. The Company conducts research in cooperation with academic institutions and research centers and supports its activities through patent protection and commercialization of developed technologies in domestic and international markets.
Directors
- Konrad Palka CMG
- Marzena Wieczorkowska VMG
- Katarzyna Konopacka CAO
- Jan Adamus SUB
- Jacek Dauenhauer SUB
- Agnieszka Dziki SUB
- Anna Janicka SUB
- Zbigniew Molenda SUB
- Anna Sysa-Jedrzejowska SUB
- Jacek Szwajcowski SUB
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- April 17th, 2008
- Public Since
- August 25th, 2008
- No. of Employees
- 7
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 11,137,758
- Address
- ul. Gdanska 47/49, LODZ, 90-729
- Web
- https://www.pharmena.eu
- Phone
- +48 422807707
- Contact
- Magdalena Michalewska
- Auditors
- KPW Audytor sp. zoo
Latest News for PHR
Upcoming Events for PHR
Q3 2026 Pharmena SA Earnings Release
Similar to PHR
4Mass SA
Warsaw Stock Exchange
Auxilia SA
Warsaw Stock Exchange
Delko SA
Warsaw Stock Exchange
Dr Miele Cosmed SA
Warsaw Stock Exchange
Euro-Tax pl SA
Warsaw Stock Exchange
FAQ
As of Today at 22:40 UTC, shares in Pharmena SA are trading at PLN2.99. This share price information is delayed by 15 minutes.
Shares in Pharmena SA last closed at PLN2.99 and the price had moved by -11.8% over the past 365 days. In terms of relative price strength the Pharmena SA share price has underperformed the FTSE Global All Cap Index by -20.47% over the past year.
There is no consensus recommendation for this security.
Find out morePharmena SA does not currently pay a dividend.
Pharmena SA does not currently pay a dividend.
Pharmena SA does not currently pay a dividend.
To buy shares in Pharmena SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN2.99, shares in Pharmena SA had a market capitalisation of PLN33.30m.
Here are the trading details for Pharmena SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: PHR
Based on an overall assessment of its quality, value and momentum Pharmena SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pharmena SA is PLN16.10. That is 438.46% above the last closing price of PLN2.99.
Analysts covering Pharmena SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmena SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -14.87%.
As of the last closing price of PLN2.99, shares in Pharmena SA were trading -8.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pharmena SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN2.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pharmena SA's management team is headed by:
- Konrad Palka - CMG
- Marzena Wieczorkowska - VMG
- Katarzyna Konopacka - CAO
- Jan Adamus - SUB
- Jacek Dauenhauer - SUB
- Agnieszka Dziki - SUB
- Anna Janicka - SUB
- Zbigniew Molenda - SUB
- Anna Sysa-Jedrzejowska - SUB
- Jacek Szwajcowski - SUB